B chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of slow-dividing and long-lived monoclonal B cells arrested at the intermediate stage of their differentiation . We previously showed that interleukin 4 (IL4) not only inhibits but also prevents the proliferation of B-CLL cells. We report here that IL-4 protects the B-CLL cells from death by apoptosis (programmed cell death [PCD]) . IL-4 inhibits spontaneous and hydrocortisone (HC)-induced PCD of highly purified B cells from 12 unselected CLL patients, as shown by sustained cell viability and lack of DNA fragmentation . IL1, -2, -3, -5, -6, -7, tumor necrosis factor a, and transforming growth factor (3 have no protective effect . The in vitro rescue from apoptosis by IL-4 is reflected by an increased expression of Bcl-2 protein, a proto-oncogene directly involved in the prolongation of cell survival in vivo and in vitro. Hence, IL-4-treated B-CLL cells express significantly more Bcl-2 than unstimulated, HC-treated, or fresh B-CLL cells. Furthermore, subcutaneous injection of IL4 into one CLL patient enhances Bcl-2 protein expression in the leukemic B cells . These data may suggest that IL-4 prevents apoptosis of B-CLL cells using a Bcl-2-dependent pathway. Given our recent observations that fresh T cells from B-CLL patients express IL-4 mRNA, we propose that IL-4 has an essential role in the pathogenesis of CLL disease, by preventing both the death and the proliferation of the malignant B cells .
Programmed cell death (PCD ;t or apoptosis) is a common form of cell deletion that can be activated in different cell types in response to a number of physiologically relevant stimuli. This process is usually accompanied by the cleavage of host chromatin into nucleosome-size fragments of -200 by appearing as a typical ladder pattern (1) . To date, a specific endonuclease or internucleosomal activity has not been purified. Triggering of T cells within the thymus with anti-CD3 antibodies (2) , superantigens (3), or specific peptides (4), or exposure of the thymocytes to glucocorticoids (5), leads to apoptosis. In contrast, in the germinal centers of lymph nodes, the selection of B lymphocytes that produce highaffinity antibodies is achieved by prevention from apoptosis for those cells that receive a positive signal after antigen recognition by their Ig receptors (6) . Similarly, factor-dependent cell lines undergo apoptosis after disappearance ofthe stimulus, such as removal of growth factors from hematopoietic precursors (7) .
Bcl-2 is a unique proto-oncogene that plays an important 1 Abbreviations used in this paper. HC, hydrocortisone; PCD, programmed cell death .
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role in cell survival. It was first isolated from the breakpoint of the translocation between chromosomes 14 and 18 frequently found in the neoplastic cells of patients with indolent follicular B cell lymphoma (8) . In normal tissues, Bcl-2 expression is topographically confined to the zones of surviving B cells in germinal centers or surviving mature thymocytes in the medulla (9) : Infection with Bcl-2 retrovirus prevents PCD occurring in some pro-B cell lines upon IL-3 deprivation (10) . Gene transfer into several cell types has confirmed that Bcl-2 acts by inhibiting cell loss rather than by stimulating cell proliferation (11) . Bcl-2 cooperates with c-myc to promote proliferation of B cell precursor (10) , and doubly transgenic mice (ew-Bcl-2/myc) develop tumors much faster than eg-myc mice, suggesting that prolonged B cell life may increase tumor incidence (12) . A similar synergy between Bcl-2 and c-myc has been extended to T cells in which combined transfer of the two genes enhances tumorogenicity of human T lymphoid cell line into athymic mice (13).
It was recently demonstrated that Bcl-2 enhances T cell survival using Bcl-2 transgenic mice expressing the transgene in the T cell lineage (14, 15) . Thymocytes of Bcl-2 transgenic strains not only exhibit an increased survival when cultured in the absence of growth factors but also resist multiple forms of apoptosis, including treatment with glucocorticoids, anti-CD3, and y radiation. Interestingly, clonal deletion of T cells that recognize endogenous superantigens is still occurring, suggesting the existence of a Bcl-2-independent pathway.
Chronic lymphocytec leukemia (CLL) is characterized by the accumulation of monoclonal long-lived B-CLL cells arrested at the intermediate stage of their differentiation (16) . B-CLL cells enter into apoptosis either spontaneously when cultured in vitro (17) or after incubation with glucocorticoids, Caz+ ionophore, and anti-Ig antibodies (18) . We previously reported that glucocorticoid hormone (hydrocortisone [HC] ) is absolutely required with IL-4 to induce the differentiation of unfractionated CLL cells into IgE-producing cells (19) . We therefore examined whether IL-4 would prevent HC-induced PCD in these leukemic cells. Here we report that IL4 inhibits spontaneous and HC-induced apoptosis in highly purified B cells from unselected CLL patients and upregulates their Bcl-2 expression .
Materials and Methods CLL Samples. 13 CLL patients were examined in the present study. Their age range was from 39 to 70 yr. Their peripheral blood contained 40-90 x 10" leukocytes/mm" of which 60-90% were lymphocytes . Flow cytometry analysis indicated that their B-CLL cells coexpressed CD20, CD5, and CD23 ; nine patients were IgM X and four patients IgM K . Patients 1-7 were at clinical stage Rai 0 (n = 2), Rai I (n = 1), and Rai III (n = 4), and patients 8-12 were at Rai 0 (n = 2) and Rai III (n = 3) . 10 patients were not receiving therapy at the time of the study. Patients 7 and 10 were administered oral prednisone for a consecutive 5 d before the study. Patient 13 (Rai IV) belonged to the preclinical study initiated to assess the antiproliferative effect of ILA in CLL disease (20) . He received subcutaneous injections of rIL4 (100/Ag/m2 ) for a consecutive 5 d with no significant side effects .
Cell Separation and Culture Conditions. PBMC from CLL patients (>90% CD5 and CD20 positive) were isolated with Lympho Prep (Cederlane Laboratories, Ontario, Canada). Highly purified B cells (no detectable CD3-or CD14-positive cells) were negatively selected by a combination of rosetting (twice) with aminoethylisothiouronium bromide-treated SRBC, adherence to plastic, and treatment with L-leucine ester. Highly purified B-CLL cells were incubated at 2.5 x 106/ml (48-well flat-bottomed plate) in HB101 serum-free medium for a culture period time of 24-48 h. HC (Sigma Chemical Co., St . Louis, MO), was used at 10 -5 M or 5 x 10 -4 M according to dose-response curves ( Fig . 1) twice with PBS and pelleted by centrifugation at 200 g for 5 min at room temperature . DNA was isolated using a slightly modified procedure as described (21) . Briefly, cell pellets (2 .5 x 106) were resuspended in cell lysis buffer (10 mM EDTA, 50 mM Tris [pH 8], containing 0.5% [wt/vol] N-laurylsarcosine and 0.5 14g/ml proteinase K) and incubated for 1 h in a 50°C water bath . RNase A was then added to a concentration of 0.25 mg/ml and incubation was prolonged for 1 h at 50°C . The DNA preparations were then extracted (twice) with buffered phenol (Sigma Chemical Co .), followed by two chlorophorm/isoamyl alcohol (24:1) extractions for removal of protein and residual traces of phenol . DNA preparations were then brought to 1.5 vol by the addition of 10 mM Tris-HCL, pH 8, 1 mM EDTA (TE buffer), and were centrifuged at 14,000 g to separate intact from fragmented chromatin. The supernatants, containing fragmented DNA, were placed in separate tubes and DNA was precipitated with 0.5-vol ammonium acetate (2 M) and 2 vol of ethanol at -70°C for 24 h. The DNA precipitates were recovered by centrifugation at 13,000 g for 15 min, air dried for 1 h at room temperature, and resuspended in TE buffer. (22) . Briefly, cell lysates were obtained by sonicating cells for 20 s and boiling for 5 min in 50 mM Tris buffer, pH 6.8 with 2% SDS, 2% 2-ME, 10% glycerol, and 0.1% bromophenol blue . Samples containing lysates of 4, 2, or 1 x 106 cells in 20 tt1 were separated by discontinuous electrophoresis on a 10% acrylamide gel and blotted onto nitrocellulose filter. Blotted filters were blocked for 2 h using a 5 % suspension of dried skimmed milk in Tris buffer, pH 7.5 (milk TBS) . The filter was then incubated at 4°C with anti-Bcl-2 mAb (10% supernatant) (kindly given to us by Dr. D. Y Mason, Headington, Oxford) in 5% milk TBS. After overnight incubation, the filter was washed and further incubated for 1 h at 20°C with 1:5,000 rabbit anti-mouse Ig (Dako Corp ., Santa Barbara, CA) in 5% milk TBS, washed, and incubated for 1 h with "'I-labeled protein A (Amersham Corp ., Arlington Heights, IL) diluted at 0.1 t&Ci/ml in 5% milk TBS. After further washing, the filter was exposed from 4 to 48 h. Quantitative analysis was performed by either cutting the bands from the filter and counting in a gamma counter (in cpm) or by scanning densitometry (GS300 ; Hoefer Scientific, San Francisco, CA) (relative intensity units) . Protein molecular weight standards (Rainbow TM ; Amersham Corp.) were run with each gel.
Electron Microscopy. For the morphological studies, the cells were fixed with 1% glutaraldehyde in 0.1 M phosphate buffer, post-fixed with 1% osmium tetroxide, and embedded in Epon according to routine techniques . For electron microscopy, the thin sections were mounted on nickel grids and examined with an electron microscope (410; Philips Electronics Instruments, Inc., Piscataway, NJ) staining with uranyl acetate and lead citrate .
Results

IL4
Rescues B-CLL Cells from Their Entry into Apoptosis. We first show that HC significantly decreases cell via- bility of highly purified B cells isolated from unselected CLL patients (n = 7), as determined by trypan blue dye exclusion, and that this effect is completely prevented by IL4 (Table  1) . Maximal HC-induced cell death is obtained after a 2-d culture ( Fig. 1 A) , and IL4 exerts its protective effect from day 1 to 3 . This protective effect may be prolonged until day 5 (not shown) . The concentrations of HC (5 x 10 -4 M) and IL4 (10 ng/ml) used throughout the study have been selected on the basis of dose-response curves (Fig. 1, B and C) and of our previous report indicating that B-CLL cells differentiate into IgE-secreting cells under these conditions (19) . Morphological examination of the HC-treated B-CLL cells at the electron microscope (Fig. 2) demonstrates the occurrence of apoptotic cells at different stages . Also, the typical "ladder" DNA degradation observed during the process of apoptosis upon exposure to HC totally disappears in the presence of IL-4 ( in their B cells, strongly supporting the view that IL4 is indeed capable of upregulating Bcl-2 expression in the malignant B cells (Fig. 8) . Of note, the efficacy of IL-4 administration is substantiated by a parallel increase in surface CD23 expression (from 23 to 98% CD23-positive cells) in the same leukemic B cells. Figure 5 . The rescue of B-CLL cells from apoptic death is restricted to 11,4 . B-CLL cells from patient 9 were cultured for 48 h in the absence or presence of HC (5 x 10 -4 M) with or without 11 .1a (1 ng/ml), IL2 (20 U/ml), I1r3 (10 ng/ml), 114 (10 ng/ml),11r5 (1/500), IL6 (500 U/ml), I1r7 (1,000 U/ml), TGF-0 (2 ng/ml), TNF-ot (25 ng/ml), sCD23 (25 ng/ml), or sCD23 and II,1ot . B-CLL cells were also incubated with 114 in the absence of HC. Shown is one representative patient out of two.
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Discussion
ILA is a T cell-derived multifunctional cytokine, originally described as B cell stimulatory factor (BSF-1), for normal preactivated human and mouse B cells (27) . We and others recently reported that ILA is a very potent antiproliferative agent for B-CLL cells by showing that IL4 not only blocked but also prevented the proliferation of the leukemic B cells to various stimuli (i.e., IL-2, IFN-cx, TNF-a, and low molecular weight B cell growth factor) (28, 29) . In this report, we present a novel function for IL4 in CLL, in that IL4 protects B-CLL cells from programmed cell death . IL4 prevents both glucocorticoid-induced and spontaneous apoptosis in B-CLL cells, as shown by sustained cell viability (trypan blue exclusion and flow cytometry) and absence of DNA fragmentation in B-CLL cells cultured in the presence of IL4. The high degree of variability in the amount of spontaneous or HC-induced cell death observed in different CLL samples is in keeping with previous reports (17, 18) and is not correlated with the phenotype of the B-CLL clones (not shown) . The effect of IL4 is specific as it is overcome by anti-IL4-a. neutralizing mAb (not detailed) . Moreover, IIJ1, -2, -3, -5, -6, -7, TNF-a, and TGF-/3 have no protective effect.
The ability of IIA to rescue B-CLL cells from apoptosis contrasts with its lack of protective effect on spontaneous PCD of germinal center B cells (6), on ionomycin-induced apoptosis of tonsillar B cells (30) , or on apoptosis of group I Burkitt lymphoma cells (31) . It is relevant to note that IL4 also inhibits ionomycin-induced PCD in B-CLL cells as well as in umbilical cord blood B cells (M . Sarfati, personal observations), strongly suggesting that the protective effect of IL-4 is more related to the biology of the B-CLL cell or its normal cellular counterpart rather than to the pathways used to induce its apoptosis . In opposition to B-CLL cells, IL-2 blocks ionomycin-induced apoptosis in normal B cells (30) . Similarly, CD23 in combination with IL1ot rescue germinal center B cells (centrocytes) from their entry into apoptosis (23), whereas they have only a slight effect on B-CLL cells, suggesting that IL4 does not mediate its protective effect via the upregulation of CD23. Supporting this view, anti-CD23-neutralizing mAb does not inhibit the IL-4 rescue pathway (M. Sarfati, personal observations) .
Occupancy of the surface Ig receptor for antigen protects centrocytes from PCD (6), whereas it induces PCD in normal tonsillar B cells, B-CLL cells (18), and in B lymphoma cell lines (32) , leading to the notion that the ability to induce apoptotic cell death may depend on the differentiation stage of the B cell . Signaling through CD40 antigen also prevents cell death in both centrocytes and Burkitt lymphoma cell lines (6, 23) . However, anti-CD40 has no protective effect in B-CLL cells (not shown) . So far, the only common agent described, capable of preventing PCD in both normal and leukemic CLL B cells, is PMA, an activator of protein kinase C (PKC) (18, 30) . These observations suggest that activation of PKC is a common pathway to desensitize the cells to PCD . Hence, PMA also prevents apoptotic cell death in human thymocytes incubated with anti-CD3 antibodies (33) . Finally, activation of EBVlatent genes protects human B cells from apoptotic death (31) . This protective effect has been recently attributed to the latent membrane protein (IMP 1) (34 Bcl-2 is unique among proto-oncogenes, being localized in the inner mitochondrial membrane and extending cell survival by inhibiting programmed cell death (26) . The Bcl-2 gene was first discovered at the breakpoint of the translocation between chromosomes 14 and 18 (t [14 ;18]) found in most follicular B cell lymphomas and some diffuse large cell lymphomas (8) . It was also reported that the rearrangement of the Bcl-2 gene occurs in a significant fraction (10%) of B-CLLs, with a preferential linkage to the Ig light chain gene (35) . However, recent reports indicate that most follicular and diffuse lymphomas, as well as all CLL cases lacking Bcl-2 rearrangement, display intense to intermediate Bcl-2 staining (24, 25) , suggesting that mechanisms other than classic translocation may be deregulating Bcl-2 expression .
Our present study shows that the protective effect of IL4 is associated with an enhanced Bcl-2 expression in the leukemic B cells . Of note, activation of centrocytes by signals that prevent their entry into apoptosis (i.e., anti-CD40 mAb, or sCD23 and IL-1) also induces Bcl-2 expression (22) . Our data indicate that various levels of Bcl-2 expression are observed in fresh B cells from all CLL cases examined . Nevertheless, IL4-treated B-CLL cells express significantly more Bcl-2 protein than freshly isolated, unstimulated, or HC-treated B-CLL cells, indicating that IIA upregulates Bcl-2 in vitro . Interestingly enough, subcutaneous injection of IL4 into one B-CLL patient (Rai IV) upregulates Bcl-2 expression in the leukemic B cells. Recent studies have shown that glucocorticoid-induced apoptosis in the thymus is Bcl-2 dependent, while clonal deletion appears to be Bcl-2 independent (14, 15) . We therefore propose that IL4 inhibits HC-induced PCD of B-CLL cells via their upregulation of Bcl-2 without ruling out the existence of an independent pathway.
Given our recent observations that freshly isolated T CLL cells, which are comprised of a very low ratio of CD4+/ CD8+ cells, express the IL4 gene (36) and that HC suppresses IL4 production by activated normal T cells (37) , the glucocorticoid-induced PCD in CLL may be explained by
